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Abstract.
The in vivo toxicity profiles in mice and the antitumour activity in tumour bearing mice were screened
for four di-n-butyltin and five triorganotin carboxylates, di-n-butyltin diterebate (5),
bis(phenylacetate) (6), bis(deoxycholate) (7), bis(lithocholate) (8), tri-n-butyltin terebate (9),
cinnamate (10), and triphenyltin terebate (11).
At their maximum tolerated dosis (MTD), no antitumour effect (T/C .-1) was observed for the
compounds 5, 7, 9, 10 and 11. The compounds 6 (T/C 0.51) and 8 (T/C 0.42) showed clear
antitumour activity after single dose administration and might therefore be of interest for further
antitumour activity studies.
Introduction
Organotin carboxylates often exhibit significant in vitro antitumour activities (Bou&lam,
1992)(Bou&lam, 1993)(Gielen, 1996a)(Gielen, 1996b)(Gielen, 1996c). The in vivo toxicity profiles
in mice and the antitumour activity in tumour bearing mice (Gielen, 1995) were screened for four di-
n-butyltin carboxylates, di-n-butyltin bis(2,4-dihydroxybenzoate) (1), bis(2,5-dihydroxybenzoate)
(2), bis(pentafluorophenylacetate) (3), and bis[di-n-butyl(pentafluorophenylacetato)tin] oxide (4)
(Gielen, 1996d).
All compounds revealed similar in vitro chemosensitivities in two cell lines, C26-10 and C26-A, two
murine undifferentiated colon carcinoma cell lines. With all compounds tested, not only cell growth
was inhibited in vitro, but also cell kill was achieved. At their maximum tolerated dose (MTD), 1 and
4 were inactive in vivo against colon 26 tumours in Balb/C mice whereas compounds 2 and 3
showed slight in vivo antitumour activity. However, the cut-off level for the growth delay factor
(GDF) (>1) was not reached. With the exception of 2 administered with a single dose and 3 with the
2 doses protocol, treatment with these compounds did not increase the life span of all mice.
Repeated administration of compound 2 did not improve the antitumour activity compared to single
dose administration.
An additional set of compounds, active in vitro, four di-n-butyltin and five triorganotin carboxylates,
namely di-n-butyltin diterebate (5) (Gielen, 1997), bis(phenylacetate) (6), bis(deoxycholate) (7)
(Willem, 1997a), bis(lithocholate) (8) (Willem, 1997a), tri-n-butyltin terebate (9) (Gielen, 1997),
cinnamate (10) (Willem, 1997b), and triphenyltin terebate (11) (Gielen, 1997), were subjected to
further investigations. In vivo toxicity and antitumour screening results are presented.
Materials and Methods
The structures of the seven compounds screened are depicted in figure 1. Their synthesis and
characterization were described earlier (Gielen, 1997)(Willem, 1997a) (Willem, 1997b).
Toxicity and in vivo screening.
The experimental procedure was described earlier (Gielen, 1996d).
The test compounds were dissolved in DMSO to a concentration ranging from 50 to 100 mg/ml and
diluted to 10 mg/ml in arachidis oil, which was also used for further dilutions. Occasionally the
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DMSO had to be acidified or made alkaline to get a clear solution. The amount of DMSO could not
be increased since mice do not tolerate more than 1%. Mice were injected intra-peritoneally.
The MTD was defined as the dose resulting in 10-15% weight loss.
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Figure 1: Structures of compounds .5 to 11
Antitumour activity.
The murine colon tumour Colon 26 (Corbett, 1975) is maintained in our laboratory since 1983
(Peters, 1987, 1989; Van der Wilt, 1992) in Balb/c mice by s.c. transplantation in both flanks in the
thoracic region of small fragments of 1-5 mm3.
Several variants of the tumour have been characterized since its original characterization, all
displaying different properties (summarized in Van Laar, 1996). The variant used in this work,
originally described as colon 26, has been used throughout all experiments in our laboratory.
When tumours had reached a volume of 50-150 mm3, treatment was started. Tumour size was
determined by calliper measurement (length x width x height x 0,5) twice a week. The volume of the
tumours was expressed relatively to that on the first day of treatment (day 0). Antitumour activity was
evaluated by calculation of the T/C (ratio of the tumour size of the Treated mice to that of Control
mice expressed in %).
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Results and discussion
Dose-finding studies of compounds 5 to 11 in MTD studies
Initial dose-finding studies were performed with groups of 2 mice which were treated weekly for two
weeks by i.p. injection (qd7x2). Results are shown in figures 2-8 for compounds ,5 to 11. For all
tested compounds, a steep dose-toxicity relation was found. In addition, for the poorly soluble
compounds 8 and 11, the toxicity was unpredictable. For example, in a repeated experiment using
the same dose (i.e. 20 mg/kg), a completely different toxicity compared to a former experiment was
observed for these two compounds. This was probably due to the poor solubility of the compounds
in DMSO resulting in a colloidal suspension in arachidis oil, resulting in non-reproducible injection of
the compounds.
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Figure 2" Dose-finding study for compound ,5 in Balb/C mice
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Figure 3: Dose-finding study for compound 6 in Balb/C mice
+ 5 mg/kg qd7x2
---o-- 7 5 mg/kg qd7x2
+ 10 mg/kg qd7x2
Toxicity of compounds 5 to 11 in the antitumour activity studies
Based on the results obtained in the dose-finding study, for each compound, a dose was chosen
somewhat lower than the MTD dose, since experience with previous compounds demonstrated
more toxicity in tumor bearing mice. The expected toxicity should be less than 10%.
However, the toxicity in tumor (colon 26A) bearing Balb/C mice was unexpectedly high (figures 9
-1 1). For the compounds 6, 7, 8, 10 and 11, severe toxicities were observed already after one
injection. Therefore, administration of a second injection of these compounds was not acceptable.
However, for compound 10, 3/8 mice could be treated twice. The compounds ,5 and 9 were
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administered according to the schedule qd7x2. For 9, this schedule was too toxic (3/5 toxic deaths
within week)l.10
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Figure 4" Dose-finding study for compound 7 in Balb/C mice
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Figure 5" Dose-finding study for compound 8 in Balb/C mice
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Figure 6" Dose-finding study for compound 9 in Balb/C mice
+ 5 mg/kg qd7x2
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Figure 7: Dose-finding study for compound 10 in Balb/C mice
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Figure 8" Dose-finding study for compound 11 in Balb/C mice
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Figure 9: Weight loss in Balb/C mice (colon 26A)induced by compounds 5 and 9
In vivo antitumour activity
Although the compounds were too toxic to administer according to the schedule used in the dose-
finding study, conclusions can be drawn based on a single dose treatment of the colon26A bearing
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mice. The assumption was made that when even at this high dose no antitumour activity is present,
it would be unlikely that lower doses at a schedule of qd7x2 would be able to produce an
antitumour effect.
At their MTD, no antitumour effect was observed for the compounds 5, 7, 9, 10 and 11, i.e. the
T/C (see fig. 12 to 14).
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Figure 10: Weight loss in Balb/C mice (colon 26A)induced by compounds 6, 7 and 10
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Figure 11" Weight loss in Balb/C mice (colon 26A) induced by compounds 6, 8 and 11
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Figure 12: Antitumour activity of compounds 5 and 9 against Colon 26A in Balb/C mice
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The compounds 6 and 8 (see fig. 13 and 14) showed clear antitumour activity after single dose
administration (for 6 and 8, T/C equals respectively 0.51 and 0.42). The dose for both compounds
was too toxic, however. Because of the promising results obtained with compound 6 at a single
dose of 7.5 mg/kg (fig 13), the dosis was decreased to 5 mg/kg in a second experiment (fig. 14) in
order to reduce the toxicity. The reduced dose also showed a antitumour effect which was less (T/C
0.81 but showed a comparable severe toxicity.
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Figure 13" Antitumour activity of compounds 6, 7 and 10 against Colon 26A in Balb/C mice
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Figure 14: Antitumour activity of compounds 6, 8 and 11 against Colon 26A in Balb/C mice
Conclusions
The compounds 6 and 8 might be of interest for further antitumour activity studies. However, their
severe toxicity makes the results difficult to interpret. An adapted formulation for administration of
the compounds will be necessary for further evaluation of possible antitumour effects.
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